Get started
Work

Table 2 from A Phase I, Open-Label, Dose Escalation Study of Enoblituzumab in Children and Young Adults with B7-H3–Expressing Relapsed or Refractory Solid Tumors

Year: 2025
Type: other
Abstract: Patient characteristics (n = 24; median, range)
DOI: 10.1158/2767-9764.30093324
Authors: Kenneth B. DeSantes, Kimberly A. McDowell, Paul M. Sondel, Paul R. Hutson, Rosandra N. Kaplan, Julie R. Park, Meenakshi G. Hegde, Crystal L. Mackall, John M. Maris
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4414101693
Cites:
Cited by:
Related to: 10